Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sintilimab + Chemo in Resectable NSCLC
NCT06485557Phase 3Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, open-label trial of sintilimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Tangdu Hospital. Primary endpoint: Pathologic Complete Response Rate at 4 months. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06485557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485557.